keyword
MENU ▼
Read by QxMD icon Read
search

Non-Hodgkin Lymphoma B-cell

keyword
https://www.readbyqxmd.com/read/29222312/harnessing-the-power-of-the-immune-system-in-non-hodgkin-lymphoma-immunomodulators-checkpoint-inhibitors-and-beyond
#1
REVIEW
Stephen M Ansell
Non-Hodgkin lymphoma is a malignancy of B lymphocytes that typically infiltrate sites of disease, including the lymph nodes, spleen, and bone marrow. Beyond the presence of malignant cells, many immune cells are also present within the tumor microenvironment. Although these immune cells have the potential to regulate the growth of malignant B cells, intratumoral immune cells are unable to eradicate lymphoma cells and most patients with lymphoma have clinical evidence of disease progression. Recent data have identified some of the mechanisms that account for the suppressed antitumor immune response and have created opportunities for treatment to overcome the deficiencies...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222311/role-of-the-microenvironment-across-histological-subtypes-of-nhl
#2
REVIEW
Karin Tarte
Recent progress in next-generation sequencing strategies has revealed the genetic landscape of B-cell non-Hodgkin lymphoma, but the tumor microenvironment is increasingly recognized as crucial to sustaining malignant B-cell survival and growth, subclonal evolution, and drug resistance. The tumor niche is made up of a dynamic and organized network of strongly heterogeneous immune and stromal cell subsets characterized by specific phenotypic, transcriptomic, and functional features. Nonmalignant cell recruitment and plasticity are dictated by lymphoma B cells, which convert their surrounding microenvironment into a supportive niche...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222274/nodular-lymphocyte-predominant-hodgkin-lymphoma-a-unique-disease-deserving-unique-management
#3
REVIEW
Dennis A Eichenauer, Andreas Engert
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidence of 0.1 to 0.2/100 000/y. Compared with the more common subtypes of classical Hodgkin lymphoma, NLPHL is characterized by distinct pathological and clinical features. Histologically, the disease-defining lymphocyte predominant cells consistently express CD20 but lack CD30. Clinically, NLPHL mostly has a rather indolent course, and patients usually are diagnosed in early stages. The prognosis of early-stage NLPHL is excellent, with progression-free survival and overall survival rates exceeding 90% after involved-field radiotherapy (IF-RT) alone (stage IA) or combined modality treatment consisting of a brief chemotherapy with 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by IF-RT (early stages other than stage IA)...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29212420/durable-response-after-vncop-b-and-rituximab-in-an-elderly-patient-with-high-grade-b-cell-lymphoma
#4
Emanuele Cencini, Alberto Fabbri, Luana Schiattone, Francesco Gentili, Maria Antonietta Mazzei, Monica Bocchia
OBJECTIVES AND METHODS:  High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Promising results have been reported with more intensive regimens but this strategy is not suitable for elderly or unfit patients. Rituximab in association with cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone (R-VNCOP-B) demonstrated high efficacy and manageable toxicity as first-line treatment for elderly aggressive non-Hodgkin lymphoma patients...
December 6, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/29212067/lenalidomide-maintenance-after-r-chop-therapy-in-diffuse-large-b-cell-lymphoma-can-it-be-a-standard-of-care
#5
Reyad Dada
Diffuse large B-cell lymphoma is an aggressive non-Hodgkin lymphoma subtype which requires immediate treatment. Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Since R-CHOP was approved, several attempts to combine it with novel agents and/or use them as maintenance therapy failed to improve the outcome. Recently, maintenance with lenalidomide after standard immune chemotherapy showed promising results. This review discusses the most pertinent published and running studies, analyzing study design, results, and practicality...
December 7, 2017: Acta Haematologica
https://www.readbyqxmd.com/read/29207777/an-aggressive-primary-retroperitoneal-diffuse-large-b-cell-lymphoma-mimicking-a-pancreatic-neoplasm-presenting-as-duodenal-stenosis
#6
Bharadhwaj Ravindhran, Clement Prakash, Sridar Govindharaj, Noor Mohammed Shawnaz Bahnou, B Pavithra
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common histological subtype of Non-Hodgkin's Lymphoma (NHL). Primary retroperitoneal DLBCL is uncommon and has seldom been reported. Extrinsic compression of the duodenum due to lesions originating from the retroperitoneum is also rare. We present a case of a 39-year-old man who presented with inability to tolerate oral intake, abdominal pain, an upper abdominal mass and postprandial bilious vomiting caused by a large DLBCL arising from the retroperitoneum causing extrinsic compression of the duodenum...
September 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/29207179/arctigenin-induces-the-apoptosis-of-primary-effusion-lymphoma-cells-under-conditions-of-glucose-deprivation
#7
Yusuke Baba, Zenpei Shigemi, Naoko Hara, Misato Moriguchi, Marina Ikeda, Tadashi Watanabe, Masahiro Fujimuro
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of primary effusion lymphoma (PEL) and Kaposi's sarcoma. PEL is a type of non-Hodgkin's B-cell lymphoma, affecting immunosuppressed individuals, such as post-transplant or AIDS patients. However, since PEL is resistant to chemotherapeutic regimens, new effective treatment strategies are required. Arctigenin, a natural lignan compound found in the plant Arctium lappa, has been widely investigated as a potential anticancer agent in the clinical setting...
December 1, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29204260/the-evolving-role-of-targeted-biological-agents-in-the-management-of-indolent-b-cell-lymphomas
#8
REVIEW
Trent Peng Wang, John Harwood Scott, Stefan Klaus Barta
Improved understanding of the mechanisms of lymphomagenesis has resulted in a surge of development for new targeted agents. An impressive number of biological agents targeting different steps in the pathways of tumor proliferation, survival and apoptosis have become available. The management of patients with indolent non-Hodgkin lymphomas (iNHLs) is rapidly transforming with incorporation of those targeted biological agents into the front-line and relapsed/refractory setting. This review highlights several categories of novel biological agents and will discuss their potential role in the contemporary management of patients with iNHLs...
December 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/29201133/risk-of-lymphoma-subtypes-by-occupational-exposure-in-southern-italy
#9
Giovanni Maria Ferri, Giorgina Specchia, Patrizio Mazza, Giuseppe Ingravallo, Graziana Intranuovo, Chiara Monica Guastadisegno, Maria Luisa Congedo, Gianfranco Lagioia, Maria Cristina Loparco, Annamaria Giordano, Tommasina Perrone, Francesco Guadio, Caterina Spinosa, Carla Minoia, Lucia D'Onghia, Michela Strusi, Vincenzo Corrado, Domenica Cavone, Luigi Vimercati, Nunzia Schiavulli, Pierluigi Cocco
Background: Occupational exposure is known to play a role in the aetiology of lymphomas. The aim of the present work was to explore the occupational risk of the major B-cell lymphoma subtypes using a case-control study design. Methods: From 2009 to 2014, we recruited 158 lymphoma cases and 76 controls in the provinces of Bari and Taranto (Apulia, Southern Italy). A retrospective assessment of occupational exposure based on complete work histories and the Carcinogen Exposure (CAREX) job-exposure matrix was performed...
2017: Journal of Occupational Medicine and Toxicology
https://www.readbyqxmd.com/read/29200668/a-study-of-clinical-profile-of-primary-extranodal-lymphomas-in-a-tertiary-care-institute-in-south-india
#10
Ananth Pai, Thiruvengadasamy Kannan, R G Balambika, Vindhya Vasini
Context: Primary extranodal lymphoma (pENL) refers to group of disorders arising from tissues other than lymph nodes. The incidence of pENL is increasing and is probably due to better diagnostic immunophenotyping and imaging modalities. Hence, this study was undertaken to ascertain the incidence, distribution, and histological subtypes of extranodal non-Hodgkin lymphoma (NHL) in a tertiary care institute in South India. Subjects and Methods: This was a retrospective study of patients diagnosed to have histologically proven NHL...
July 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29196080/outcomes-after-allogeneic-stem-cell-transplantation-in-patients-with-double-hit-and-double-expressor-lymphoma
#11
Alex F Herrera, Scott J Rodig, Joo Y Song, Young Kim, Gabriel K Griffin, Dongyun Yang, Liana Nikolaenko, Matthew Mei, Victoria Bedell, Paola Dal Cin, Christine Pak, Edwin P Alyea, Elizabeth Budde, Robert Chen, Yi-Bin Chen, Wing C Chan, Corey S Cutler, Vincent T Ho, John Koreth, Amrita Krishnan, Joyce L Murata-Collins, Sarah Nikiforow, Joycelynne Palmer, German A Pihan, Raju Pillai, Leslie Popplewell, Steven T Rosen, Tanya Siddiqi, Aliyah R Sohani, Jasmine Zain, Larry W Kwak, Dennis D Weisenburger, David M Weinstock, Robert J Soiffer, Joseph H Antin, Stephen J Forman, Auayporn P Nademanee, Philippe Armand
Double-hit lymphomas (DHL) and double-expressor lymphomas (DEL) are associated with resistance to frontline and salvage immunochemotherapy, as well as autologous stem cell transplantation (SCT). We hypothesized that allogeneic SCT (alloSCT) could overcome the chemoresistance associated with DEL/DHL. We retrospectively studied the impact of DEL/DHL status in a multicenter cohort of patients who underwent alloSCT for relapsed/refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). 78 patients transplanted at 3 centers in whom tumor tissue was available for immunohistochemistry and FISH were enrolled; 47% had DEL and 13% had DHL...
November 28, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29195616/pet-ct-for-lymphoma-post-therapy-response-assessment-in-other-lymphomas-response-assessment-for-autologous-stem-cell-transplant-and-lymphoma-follow-up
#12
REVIEW
Shawn Karls, Hina Shah, Heather Jacene
FDG-PET/CT is an established first-line diagnostic imaging tool used in the staging of most lymphomas and for post-therapy response assessment in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). Many of the subtypes of lymphoid neoplasms classified by the World Health Organization demonstrate significant FDG-avidity or uptake; however, many guidelines and Lugano classification do not recommend the use of FDG-PET/CT in assessing response to therapy for these non-HL, non-DLBCL subtypes as a first-line diagnostic tool...
January 2018: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/29195615/pet-ct-for-lymphoma-post-therapy-response-assessment-in-hodgkin-lymphoma-and-diffuse-large-b-cell-lymphoma
#13
REVIEW
Carsten Kobe, Markus Dietlein, Dirk Hellwig
Over the course of many decades, combined chemotherapy and radiotherapy adapted to the stage of disease have become the optimal and standard treatment for Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma. Besides achieving optimized cure rates of the underlying disease, reduction of toxicity has become a major goal. Since the introduction of FDG-PET for the staging and restaging of patients with lymphoma, a high predictive value of F-18-FDG-PET in response assessment has been observed. Several PET-response-guided therapy regimens have already been established, and even more PET-adapted study designs are being tested in large study groups...
January 2018: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/29195613/interim-fdg-pet-imaging-in-lymphoma
#14
REVIEW
Andrea Gallamini, Colette Zwarthoed
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma...
January 2018: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/29193018/obesity-negatively-impacts-outcome-in-elderly-female-patients-with-aggressive-b-cell-lymphomas-treated-with-r-chop-results-from-prospective-trials-of-the-german-high-grade-non-hodgkin-s-lymphoma-trial-group
#15
K Hohloch, B Altmann, M Pfreundschuh, M Loeffler, N Schmitz, F Zettl, M Ziepert, L Trümper
To study if obesity is a risk factor in elderly patients (>60 years) with aggressive B-cell lymphoma, the outcomes of 576 elderly patients treated with rituximab in the RICOVER-60 trial were analysed in a retrospective study with regard to body mass index (BMI) and gender. Of the 576 patients, 1% had low body weight (BMI < 18·5), 38% were normal weight (18·5 ≤ BMI < 25), 42% were overweight (25 ≤ BMI < 30) and 19% were obese (BMI ≥ 30). Event-free (EFS), progression-free (PFS) and overall survival (OS) according to BMI showed no significant differences for all and for male patients...
November 28, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29188315/high-prevalence-of-hepatitis-b-virus-infection-in-patients-with-aggressive-b-cell-non-hodgkin-s-lymphoma-in-china
#16
Chaoyu Wang, Bing Xia, Qiaoyang Ning, Haifeng Zhao, Hongliang Yang, Zhigang Zhao, Xiaofang Wang, Yafei Wang, Yong Yu, Yizhuo Zhang
We retrospectively analyzed a large study to investigate the association of hepatitis B virus (HBV) with aggressive B cell non-Hodgkin's lymphoma (aggressive B-NHL) in China, where HBV is endemic. HBV was present in 39 aggressive B-NHL patients (10.46%), 13 indolent B-NHL patients (5.09%), 12 multiple myeloma (MM) patients (3.67%), and 5 solitary plasmacytoma (SP) patients (6.67%). HBV infection was significantly associated with increased risks for aggressive B-NHL (P < 0.01). HBV seems to have a very important role in the pathogenesis of aggressive B-NHL in China...
November 29, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29187222/unusual-presentation-of-plasmablastic-lymphoma-involving-ovarian-mature-cystic-teratoma-a-case-report
#17
Ita Hadžisejdić, Emina Babarović, Luka Vranić, Antica Duletić Načinović, Ksenija Lučin, Maja Krašević, Nives Jonjić
BACKGROUND: Plasmablastic lymphoma (PBL) is relatively new clinical entity described as a distinct subtype of diffuse large B-cell lymphoma (DLBCL). It is characterized by its aggressive nature and proliferation of large neoplastic cells resembling immunoblasts including cells with more obvious plasmacytic differentiation. In this case report, we describe an unexpected finding of PBL associated with a mature cystic teratoma of the ovary in a young immune competent woman. CASE PRESENTATION: A 19-year old woman was admitted to the hospital with generalized lymphadenopathy, a pelvic tumor mass measuring 35 × 30 cm and a 4 cm lump in her right breast...
November 29, 2017: Diagnostic Pathology
https://www.readbyqxmd.com/read/29182205/-large-b-cell-lymphoma-coexisting-with-castleman-s-disease-report-of-one-case
#18
Alejandro Avilés-Salas, Myrna Candelaria, Diana Brisa Sevilla-Lizcano, Sebastián Burgos
We report a 73-year-old female patient with Castleman's disease coexistent with large B cell type non-Hodgkin's lymphoma in a right axillary lymphadenopathy. An excisional biopsy was performed: microscopically, the lymph node revealed the presence of numerous plasma cells and small lymphoid cells characteristic of Castleman's disease. An analysis of another portion of the specimen revealed lymphoid cells with large abnormal nuclei gathered locally that were CDD 79+, CD 38+ and MUM-1+ as well as positive for Kaposi sarcoma-associated herpesvirus and negative for Epstein Barr virus encoded RNA-1 (EBER)...
July 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29178403/n-glycan-engineering-of-a-plant-produced-anti-cd20-hil-2-immunocytokine-significantly-enhances-its-effector-functions
#19
Carla Marusic, Claudio Pioli, Szymon Stelter, Flavia Novelli, Chiara Lonoce, Elena Morrocchi, Eugenio Benvenuto, Anna Maria Salzano, Andrea Scaloni, Marcello Donini
Anti-CD20 recombinant antibodies are among the most promising therapeutics for the treatment of B-cell malignancies such as non-Hodgkin lymphomas. We recently demonstrated that an immunocytokine (2B8-Fc-hIL2), obtained by fusing an anti-CD20 scFv-Fc antibody derived from C2B8 mAb (rituximab) to the human interleukin 2 (hIL-2), can be efficiently produced in Nicotiana benthamiana plants. The purified immunocytokine (IC) bearing a typical plant protein N-glycosylation profile showed a CD20 binding activity comparable to that of rituximab and was efficient in eliciting antibody-dependent cell-mediated cytotoxicity (ADCC) of human PBMC against Daudi cells, indicating its fuctional integrity...
November 27, 2017: Biotechnology and Bioengineering
https://www.readbyqxmd.com/read/29178090/-treatment-of-primary-gastric-lymphoma
#20
Yi Xia, Zhiwei Zhou
Stomach is the most common location of lymphoma in digestive tract, accounting for 50%-60% of gastrointestinal lymphomas. The most common histological types are low malignant mucosa-associated lymphoid tissue (MALT) lymphoma from non-Hodgkin lymphoma (NHL) and diffuse large B-cell and marginal zone B-cell lymphoma (DLBCL) from NHL. Chronic gastritis secondary to Helicobacter pylori(HP) infection has been considered a major predisposing factor for MALT lymphoma. At present, the most widely accepted initial therapy for localized disease is aimed at the eradication of HP using regimens combining antibiotics and proton-pump inhibitors...
November 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
keyword
keyword
77169
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"